Cytokinetics Stays the Course
Executive Summary
Cytokinetics claims to have implemented a far more detailed long-term strategic plan than most biotechs. That plan will be put to the test as it enters the clinic with an acute CHF compound. Until now, the company has relied on a partner (GSK) to shoulder the burden of developing its drug candidates. Now it will have to do that heavy lifting, at least for a while, on its own.
You may also be interested in...
Co-Promotes: A Marketplace Reality, But Do They Make Sense?
Co-promotions are a hallmark of today's licensing deals as biotechs try to secure their future growth. But do they make sense--for the product, or for the partners?
Co-Promotes: A Marketplace Reality, But Do They Make Sense?
Co-promotions are a hallmark of today's licensing deals as biotechs try to secure their future growth. But do they make sense--for the product, or for the partners?
Theravance: Having Cake and Eating It
Thanks to productivity, lower-risk follow-on drugs and access to a Big Pharma balance sheet, Theravance is trying to demonstrate the possibility of getting paid for doing what biotech does best: research.